Literature DB >> 29979898

Serum of Patients with Psoriasis Modulates the Production of MMP-9 and TIMP-1 in Cells of Monocytic Lineage.

Luis M Amezcua-Guerra1,2,3, Rafael Bojalil1,3, Jessica Espinoza-Hernandez4, María E Vega-Memije4, Rosa M Lacy-Niebla4, Fernanda Ortega-Springall4, Jorge Ortega-Hernández1, Fausto Sánchez-Muñoz1, Rashidi Springall1.   

Abstract

Psoriasis is triggered by several stimuli that share a systemic production of interferon (IFN)-γ and other inflammatory mediators, which are key to regulate the production of matrix metalloproteinase (MMP)-9 and its inhibitor (TIMP)-1 by cells of monocytic lineage. This study evaluates the effect of the sera of 55 patients with psoriasis and 41 non-psoriatic individuals on the production of MMP-9 and TIMP-1 in cultured monocytes from a single healthy blood donor and in U937 cells. The effect of IFN-γ stimulation was also evaluated. Serum and supernatant concentrations of IFN-γ, MMP-9, and TIMP-1 were measured by enzyme-linked immunoassays, and the MMP-9/TIMP-1 ratios were calculated. In monocytes, incubation with psoriasis' sera increased the production of MMP-9 and TIMP-1 in comparison with both baseline and monocytes incubated with non-psoriatic sera. Although the MMP-9/TIMP-1 ratio was significantly higher compared to the baseline, no differences between groups were observed. In contrast, IFN-γ stimulation in monocytes previously exposed to psoriasis' sera increased MMP-9 levels and decreased TIMP-1 levels, whereas stimulation in monocytes exposed to non-psoriatic sera did not further modify the levels of MMP-9 or TIMP-1. Consequently, the MMP-9/TIMP-1 ratio in cells exposed to psoriatic serum was significantly higher than in cells exposed to non-psoriatic sera (24.5 versus 16.7; P < 0.05). Similar results were observed in U937 cells. Therefore, our results suggest that soluble mediators in psoriatic sera may enhance the proteolytic phenotype of monocytes when stimulated with IFN-γ, which supports the existence of a primed state in the inflammatory cells of patients with psoriasis.

Entities:  

Keywords:  Interferon gamma; metalloproteases; psoriasis

Mesh:

Substances:

Year:  2018        PMID: 29979898     DOI: 10.1080/08820139.2018.1489831

Source DB:  PubMed          Journal:  Immunol Invest        ISSN: 0882-0139            Impact factor:   3.657


  4 in total

1.  Extracellular matrix alterations in the skin of patients affected by psoriasis.

Authors:  Mariana Fatima Muaccad Gama Wagner; Thérèse Rachell Theodoro; Carlos D' Apparecida Santos Machado Filho; Luiza Keiko Matsuka Oyafuso; Maria Aparecida Silva Pinhal
Journal:  BMC Mol Cell Biol       Date:  2021-10-29

2.  Mechanism of Huoluo Xiaoling Dan in the Treatment of Psoriasis Based on Network Pharmacology and Molecular Docking.

Authors:  Ke Gong; Wen Guo; Kaiqing Du; Fang Wang; Mengli Li; Jianhui Guo
Journal:  Evid Based Complement Alternat Med       Date:  2022-02-27       Impact factor: 2.629

3.  Combination of retinoids and narrow-band ultraviolet B inhibits matrix metalloproteinase 13 expression in HaCaT keratinocytes and a mouse model of psoriasis.

Authors:  Chan Xi; Chuanxi Xiong; Huiping Wang; Yuanjun Liu; Suju Luo
Journal:  Sci Rep       Date:  2021-06-25       Impact factor: 4.379

4.  Assessment of Selected Matrix Metalloproteinases (MMPs) and Correlation with Cytokines in Psoriatic Patients.

Authors:  Anna Michalak-Stoma; Joanna Bartosińska; Dorota Raczkiewicz; Małgorzata Kowal; Dorota Krasowska; Grażyna Chodorowska
Journal:  Mediators Inflamm       Date:  2021-06-29       Impact factor: 4.711

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.